Search Result

Results for "

alpha-secretase

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (1) Amyloid-β (3) Apoptosis (1) ATM/ATR (1) Biochemical Assay Reagents (1) Calcium Channel (2) Cholecystokinin Receptor (1) Cholinesterase (ChE) (1) EGFR (2) ERK (2) Ferroptosis (1) Fluorescent Dye (1) Fungal (1) GABA Receptor (3) HIF/HIF Prolyl-Hydroxylase (1) Interleukin Related (1) MMP (1) mTOR (1) NF-κB (1) Notch (1) PACAP Receptor (2) Phosphodiesterase (PDE) (3) PTEN (1) Reactive Oxygen Species (ROS) (2) Reference Standards (1) VEGFR (1) γ-secretase (1)
By Research Areas:	Cancer (1) Infection (2) Inflammation/Immunology (3) Metabolic Disease (1) Neurological Disease (8)

By Targets:

Akt (1)

Amyloid-β (3)

Apoptosis (1)

ATM/ATR (1)

Biochemical Assay Reagents (1)

Calcium Channel (2)

Cholecystokinin Receptor (1)

Cholinesterase (ChE) (1)

EGFR (2)

ERK (2)

Ferroptosis (1)

Fluorescent Dye (1)

Fungal (1)

GABA Receptor (3)

HIF/HIF Prolyl-Hydroxylase (1)

Interleukin Related (1)

MMP (1)

mTOR (1)

NF-κB (1)

Notch (1)

PACAP Receptor (2)

Phosphodiesterase (PDE) (3)

PTEN (1)

Reactive Oxygen Species (ROS) (2)

Reference Standards (1)

VEGFR (1)

γ-secretase (1)

By Research Areas:

Cancer (1)

Infection (2)

Inflammation/Immunology (3)

Metabolic Disease (1)

Neurological Disease (8)

Inhibitors & Agonists

Peptides

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P0221

PACAP (1-38), human, ovine, rat 5 Publications Verification Pituitary Adenylate Cyclase Activating Polypeptide 38	PACAP Receptor ERK EGFR Reactive Oxygen Species (ROS) Calcium Channel	Infection Neurological Disease
PACAP (1-38), human, ovine, rat is a PAC₁ receptor agonist. PACAP (1-38), human, ovine, rat binds to PACAP type I receptor, PACAP type II receptor VIP1, and PACAP type II receptor VIP2 with IC₅₀s of 4 nM, 2 nM, and 1 nM, respectively. PACAP (1-38), human, ovine, rat increases the α-secretase activity. PACAP (1-38), human, ovine, rat elevates cytosolic Ca ²⁺, increases proliferation and increases phosphorylation of extracellular regulates kinase (ERK) and the epidermal growth factor receptor (EGFR). PACAP (1-38), human, ovine, rat demonstrates potent, efficacious, and sustained stimulatory effects on sympathetic neuronal NPY and catecholamine production. PACAP (1-38), human, ovine, rat can be used for neurotrophic and neuroprotective research .

HY-100936

Etazolate hydrochloride SQ 20009; EHT 0202 hydrochloride	Phosphodiesterase (PDE) GABA Receptor	Neurological Disease Inflammation/Immunology
Etazolate hydrochloride (SQ 20009) is an orally active, selective inhibitor of type 4 phosphodiesterase (PDE4) with an IC₅₀ of 2 μM. Etazolate hydrochloride is a γ-aminobutyric acid A (GABA_A) receptor regulator. Etazolate hydrochloride is an *α-secretase* activator and induced the production of soluble amyloid precursor protein (sAPPα). Etazolate hydrochloride, a pyrazolopyridine class derivative, increases cAMP levels. Etazolate hydrochloride has anxiolyticlike, antidepressant-like and anti-inflammatory effects .

HY-N11709

Theasaponin E1	Apoptosis VEGFR ATM/ATR PTEN Akt mTOR HIF/HIF Prolyl-Hydroxylase NF-κB Notch Cholinesterase (ChE) Amyloid-β γ-secretase Ferroptosis Fungal	Infection Neurological Disease Metabolic Disease Cancer
Theasaponin E1 is an orally effective tea saponin. Theasaponin E1 inhibits the proliferation of cancer cells by activating apoptosis. Theasaponin E1 inhibits angiogenesis in ovarian cancer cells and HUVECs by reducing the expression of VEGF. Theasaponin E1 upregulates the phosphorylation level of ATM protein and the expression level of PTEN protein in cancer cells, decreases the phosphorylation levels of Akt, mTOR, p70S6K and 4E-BP1 proteins, downregulates the expression of *HIF-1α* and NF-κB, and reduces the protein expression of Notch ligands Dll4 and Jagged1. Theasaponin E1 exerts neuroprotective effects by inhibiting the activity of acetylcholinesterase, activating *α-secretase* and neprilysin, reducing the concentration of Aβ, and inhibiting the activities of *β-secretase* and *γ-secretase. Theasaponin E1 exhibits toxic effects on cancer cells and quinone reductase-inducing activity, and inhibits tumor growth in vivo. Theasaponin E1 induces ferroptosis* in Pomacea canaliculata by synergistically disrupting cholesterol homeostasis and sphingolipid metabolism. Theasaponin E1 possesses anti-biofilm activity against Candida albicans. Theasaponin E1 can be used in the research of ovarian cancer, obesity, Alzheimer's disease and fungal infections .

HY-P11540

CCKBR agonist-1	Cholecystokinin Receptor MMP Amyloid-β	Neurological Disease
CCKBR agonist-1 (Compound 3r1) is a Gq-protein-preferring cholecystokinin B receptor (CCKBR) agonist with an EC₅₀ of 35 pM. CCKBR agonist-1 significantly increases the survival rate of neurons, with an EC₅₀ of 37 pM. CCKBR agonist-1 can improve the cognitive decline in mice by upregulating α-secretase (ADAM10) and calcium signaling molecule PLCB4, reduce the number of amyloid β (Aβ) plaques, and promote long-term potentiation (LTP). CCKBR agonist-1 can be used for the study of Alzheimer's disease .

HY-P10189

α-Secretase Substrate, Fluorogenic	Biochemical Assay Reagents	Others
α-Secretase Substrate, Fluorogenic is α-secretase fluorogenic substrate that can be used to test α-secretase activity .

HY-P10163

α-Secretase Substrate II, Fluorogenic	Fluorescent Dye	Others
α-Secretase Substrate II, Fluorogenic is an internally quenched fluorogenic peptide substrate for α-Secretase that contains the α-secretase cleavage site of β-Amyloid precursor protein (APP) .Ex/Em = 340/490 nm

HY-106044

Etazolate SQ 64442	Phosphodiesterase (PDE) GABA Receptor Interleukin Related	Neurological Disease Inflammation/Immunology
Etazolate (SQ 64442) is a *α-secretase* activator, selective PDE4 inhibitor, selective GABA_A receptor modulator. Etazolate reduces IL-1β levels Etazolate exerts a dose-dependent anti-inflammatory and anti-œdematous effect accompanied by lasting memory improvement. Etazolate produces an antidepressant-like effect .

HY-100936R

Etazolate hydrochloride (Standard) SQ 20009 (Standard); EHT 0202 hydrochloride (Standard)	Reference Standards Phosphodiesterase (PDE) GABA Receptor	Neurological Disease Inflammation/Immunology
Etazolate (hydrochloride) (Standard) is the analytical standard of Etazolate (hydrochloride). This product is intended for research and analytical applications. Etazolate hydrochloride (SQ 20009) is an orally active, selective inhibitor of type 4 phosphodiesterase (PDE4) with an IC50 of 2 μM. Etazolate hydrochloride is a γ-aminobutyric acid A (GABAA) receptor regulator. Etazolate hydrochloride is an α-secretase activator and induced the production of soluble amyloid precursor protein (sAPPα). Etazolate hydrochloride, a pyrazolopyridine class derivative, increases cAMP levels. Etazolate hydrochloride has anxiolyticlike, antidepressant-like and anti-inflammatory effects .

HY-P0221A

PACAP (1-38), human, ovine, rat TFA Pituitary Adenylate Cyclase Activating Polypeptide 38 TFA	PACAP Receptor ERK EGFR Reactive Oxygen Species (ROS) Calcium Channel	Neurological Disease
PACAP (1-38), human, ovine, rat TFA is a PAC₁ receptor agonist. PACAP (1-38), human, ovine, rat TFA binds to PACAP type I receptor, PACAP type II receptor VIP1, and PACAP type II receptor VIP2 with IC₅₀s of 4 nM, 2 nM, and 1 nM, respectively. PACAP (1-38), human, ovine, rat TFA increases the α-secretase activity. PACAP (1-38), human, ovine, rat TFA elevates cytosolic Ca ²⁺, increases proliferation and increases phosphorylation of extracellular regulates kinase (ERK) and the epidermal growth factor receptor (EGFR). PACAP (1-38), human, ovine, rat TFA demonstrates potent, efficacious, and sustained stimulatory effects on sympathetic neuronal NPY and catecholamine production. PACAP (1-38), human, ovine, rat TFA can be used for neurotrophic and neuroprotective research .

HY-118972

TPI-1917-49	Amyloid-β	Neurological Disease
TPI-1917-49 is an agent that can cross the blood-brain barrier and reduce amyloid β (Aβ). TPI-1917-49 reduces the production of Aβ peptide segments by promoting the non-amyloidogenic pathway of amyloid precursor protein (APP) (increasing the generation of sAPPα mediated by α-secretase). TPI-1917-49 reduces amyloid plaques in mouse models. TPI-1917-49 can be used in Alzheimer's disease research .

Cat. No.	Product Name	Target	Research Area